← Leaderboards
John F Dipersio
Washington University
$33,235,840
Attributed
$38,685,957
Total exposure
19
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,685,957 · 19
By mechanism
K12$10,900,235 · 1
R35$7,066,469 · 1
P50$5,663,647 · 5
P01$5,580,039 · 3
R01$5,198,474 · 3
U54$2,312,193 · 3
Top collaborators
- Ramaswamy Govindan14 shared
Most similar at Washington University
Same institution · by research overlap
- Samuel H Speck$26,128,328
- David R Piwnica-Worms$22,122,563
- Thomas G. Diacovo$10,076,014
- Todd A Fehniger$7,042,287
- Iskra Pusic$628,090
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsLeukemiaRelapseAllogenicCellsBaseT-LymphocyteIn VivoResponseBone MarrowMouse ModelRefractoryChemotherapyHematologic NeoplasmsProgramsDisease RemissionIn VitroMalignant NeoplasmsPreventTranslatingImmuneHematopoietic Stem Cell TransplantationResistanceMediating
Grant awards (88)
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$809,499
K12 · FY2025 · CA
Optimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological Malignancies$713,138
R35 · FY2025 · CA · contact PI
Project 1: Chimeric antigen receptor T-cell therapy for T cell malignancies$349,875
P50 · FY2025 · CA · contact PI
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$809,838
K12 · FY2024 · CA
Project 1: Chimeric antigen receptor T-cell therapy for T cell malignancies$335,880
P50 · FY2024 · CA · contact PI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$894,296
R35 · FY2023 · CA · contact PI
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$801,870
K12 · FY2023 · CA
Project 2 - Genomics of Allogeneic Transplantation.$436,241
P01 · FY2023 · CA · contact PI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$63,892
R35 · FY2023 · CA · contact PI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$896,700
R35 · FY2022 · CA · contact PI
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$810,000
K12 · FY2022 · CA
Project 2 - Genomics of Allogeneic Transplantation.$436,495
P01 · FY2022 · CA · contact PI
Project 6- Targeting AML using bispecific and antibody drug conjugates$255,145
P50 · FY2022 · CA · contact PI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$204,944
R35 · FY2022 · CA · contact PI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$914,570
R35 · FY2021 · CA · contact PI
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$810,000
K12 · FY2021 · CA
Project 2 - Genomics of Allogeneic Transplantation.$439,823
P01 · FY2021 · CA · contact PI
Project 4 - Targeting AML using novel bispecific and antibody-drug conjugates.$276,035
P50 · FY2021 · CA · contact PI
Project 6- Targeting AML using bispecific and antibody drug conjugates$270,342
P50 · FY2021 · CA · contact PI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$914,906
R35 · FY2020 · CA · contact PI
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$808,155
K12 · FY2020 · CA
Project 2 - Genomics of Allogeneic Transplantation.$443,912
P01 · FY2020 · CA · contact PI
Project 4 - Targeting AML using novel bispecific and antibody-drug conjugates.$324,449
P50 · FY2020 · CA · contact PI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$887,400
R35 · FY2019 · CA · contact PI
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$793,190
K12 · FY2019 · CA
Projecdt 3 - Modulation of bone environment to enhance response of bone cancers$356,975
U54 · FY2019 · CA · contact PI
Project 4 - Targeting AML using novel bispecific and antibody-drug conjugates.$319,127
P50 · FY2019 · CA · contact PI
Project 2 - Genomics of Allogeneic Transplantation.$238,509
P01 · FY2019 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$130,878
U54 · FY2019 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$20,074
U54 · FY2019 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$20,074
U54 · FY2019 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$9,166
U54 · FY2019 · CA · contact PI
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$915,000
R35 · FY2018 · CA · contact PI
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$810,000
K12 · FY2018 · CA
Projecdt 3 - Modulation of bone environment to enhance response of bone cancers$373,605
U54 · FY2018 · CA · contact PI
Project 4 - Targeting AML using novel bispecific and antibody-drug conjugates.$342,469
P50 · FY2018 · CA · contact PI
Genomics of AML Relapse$180,874
P01 · FY2018 · CA · contact PI
Project 4 - Targeting AML using novel bispecific and antibody-drug conjugates.$6,633
P50 · FY2018 · CA · contact PI
Washington University Paul Calabresi K12 Career Development Award for Clinical Oncology$807,997
K12 · FY2017 · CA
Optimizing Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Malignancies$661,623
R35 · FY2017 · CA · contact PI
Epigenetic Modulation of GvHD and GvL$431,264
P50 · FY2017 · CA · contact PI
RETARGETING AGENTS TO TREAT AML$380,068
R01 · FY2017 · CA · contact PI
Projecdt 3 - Modulation of bone environment to enhance response of bone cancers$378,745
U54 · FY2017 · CA · contact PI
Genomics of AML Relapse$330,341
P01 · FY2017 · CA · contact PI
Pilot Projects and Trans-Network Activities Core$254,449
U54 · FY2017 · CA · contact PI
WASHINGTON UNIVERSITY PAUL CALABRESI CAREER DEVELOPMENT AWARD FOR CLINICAL ONCOLO$1,043,545
K12 · FY2016 · CA
Epigenetic Modulation of GvHD and GvL$405,388
P50 · FY2016 · CA · contact PI
Projecdt 3 - Modulation of bone environment to enhance response of bone cancers$381,718
U54 · FY2016 · CA · contact PI
RETARGETING AGENTS TO TREAT AML$380,068
R01 · FY2016 · CA · contact PI
Genomics of AML Relapse$333,043
P01 · FY2016 · CA · contact PI
WASHINGTON UNIVERSITY PAUL CALABRESI CAREER DEVELOPMENT AWARD FOR CLINICAL ONCOLO$1,041,138
K12 · FY2015 · CA
TARGETING AML-STROMAL INTERACTIONS$500,179
R01 · FY2015 · CA · contact PI
Projecdt 3 - Modulation of bone environment to enhance response of bone cancers$386,509
U54 · FY2015 · CA · contact PI
RETARGETING AGENTS TO TREAT AML$380,068
R01 · FY2015 · CA · contact PI
Epigenetic Modulation of GvHD and GvL$345,391
P50 · FY2015 · CA · contact PI
Genomics of AML Relapse$332,388
P01 · FY2015 · CA · contact PI
WASHINGTON UNIVERSITY PAUL CALABRESI CAREER DEVELOPMENT AWARD FOR CLINICAL ONCOLO$884,381
K12 · FY2014 · CA
TARGETING AML-STROMAL INTERACTIONS$486,043
R01 · FY2014 · CA · contact PI
Epigenetic Modulation of GvHD and GvL$334,147
P50 · FY2014 · CA · contact PI
Genomics of AML Relapse$321,797
P01 · FY2014 · CA · contact PI
WASHINGTON UNIVERSITY PAUL CALABRESI CAREER DEVELOPMENT AWARD FOR CLINICAL ONCOLO$563,350
K12 · FY2013 · CA
TARGETING AML-STROMAL INTERACTIONS$471,871
R01 · FY2013 · CA · contact PI
Epigenetic Modulation of GvHD and GvL$340,210
P50 · FY2013 · CA · contact PI
Genomics of AML Relapse$331,123
P01 · FY2013 · CA · contact PI
TARGETING AML-STROMAL INTERACTIONS$502,925
R01 · FY2012 · CA · contact PI
Genomics of Acute Myelogenous Leukemia (AML): Relapse and Resistance Factors$335,274
P01 · FY2012 · CA · contact PI
WASHINGTON UNIVERSITY PAUL CALABRESI CAREER DEVELOPMENT AWARD FOR CLINICAL ONCOLO$107,272
K12 · FY2012 · CA
Genomics of Acute Myelogenous Leukemia (AML): Relapse and Resistance Factors$535,495
P01 · FY2011 · CA · contact PI
TARGETING AML-STROMAL INTERACTIONS$499,242
R01 · FY2011 · CA · contact PI
Res Proj 4: PET Imaging of GVHD & GVL Modulation Using Genetically-Modified...$258,040
P50 · FY2011 · CA · contact PI
OPTIMIZING ALLOGENEIC TRANSPLANTATION USING CXCR4 BLOCKADE$334,400
R21 · FY2010 · CA · contact PI
TARGETING THE CXCR4-SDF1 AXIS AS THERAPY FOR RELAPSED/REFRACTORY AML$334,400
R21 · FY2010 · CA · contact PI
Genomics of Acute Myelogenous Leukemia (AML): Relapse and Resistance Factors$299,591
P01 · FY2010 · CA · contact PI
Res Proj 4: PET Imaging of GVHD & GVL Modulation Using Genetically-Modified...$289,483
P50 · FY2010 · CA · contact PI
OPTIMIZING ALLOGENEIC TRANSPLANTATION USING CXCR4 BLOCKADE$334,400
R21 · FY2009 · CA · contact PI
TARGETING THE CXCR4-SDF1 AXIS AS THERAPY FOR RELAPSED/REFRACTORY AML$334,400
R21 · FY2009 · CA · contact PI
Genomics of Acute Myelogenous Leukemia (AML): Relapse and Resistance Factors$295,216
P01 · FY2009 · CA · contact PI
Res Proj 4: PET Imaging of GVHD & GVL Modulation Using Genetically-Modified...$292,709
P50 · FY2009 · CA · contact PI
Genomics of Acute Myelogenous Leukemia (AML): Relapse and Resistance Factors$289,917
P01 · FY2008 · CA · contact PI
Res Proj 4: PET Imaging of GVHD & GVL Modulation Using Genetically-Modified...$241,335
P50 · FY2008 · CA · contact PI
Res Proj 4: PET Imaging of GVHD & GVL Modulation Using Genetically-Modified...$245,725
P50 · FY2007 · CA · contact PI
Genetic Manipulation of T Cells--PreClinical Models$319,550
R01 · FY2005 · CA
DLI using genetically modified T cells: Phase 1 trial$313,650
R21 · FY2005 · CA
Genetic Manipulation of T Cells--PreClinical Models$319,550
R01 · FY2004 · CA
DLI using genetically modified T cells: Phase 1 trial$313,650
R21 · FY2004 · CA
Genetic Manipulation of T Cells--PreClinical Models$319,550
R01 · FY2003 · CA
Genetic Manipulation of T Cells--PreClinical Models$319,550
R01 · FY2002 · CA
Genetic Manipulation of T Cells--PreClinical Models$319,810
R01 · FY2001 · CA